- Home
- Medical news & Guidelines
- Anesthesiology
- Cardiology and CTVS
- Critical Care
- Dentistry
- Dermatology
- Diabetes and Endocrinology
- ENT
- Gastroenterology
- Medicine
- Nephrology
- Neurology
- Obstretics-Gynaecology
- Oncology
- Ophthalmology
- Orthopaedics
- Pediatrics-Neonatology
- Psychiatry
- Pulmonology
- Radiology
- Surgery
- Urology
- Laboratory Medicine
- Diet
- Nursing
- Paramedical
- Physiotherapy
- Health news
- AYUSH
- State News
- Andaman and Nicobar Islands
- Andhra Pradesh
- Arunachal Pradesh
- Assam
- Bihar
- Chandigarh
- Chattisgarh
- Dadra and Nagar Haveli
- Daman and Diu
- Delhi
- Goa
- Gujarat
- Haryana
- Himachal Pradesh
- Jammu & Kashmir
- Jharkhand
- Karnataka
- Kerala
- Ladakh
- Lakshadweep
- Madhya Pradesh
- Maharashtra
- Manipur
- Meghalaya
- Mizoram
- Nagaland
- Odisha
- Puducherry
- Punjab
- Rajasthan
- Sikkim
- Tamil Nadu
- Telangana
- Tripura
- Uttar Pradesh
- Uttrakhand
- West Bengal
- Medical Education
- Industry
Once Daily Vildagliptin 100 mg SR as safe, effective as Vildagliptin 50 mg twice daily add on to Metformin in Indian Diabetics: Discussion on Indian Study Results
Overview
Vildagliptin, an oral hypoglycemic agent, acts by inhibiting the dipeptidyl peptidase-4 enzyme. The clinical efficacy and safety of vildagliptin monotherapy or in combination with metformin have been demonstrated.
Vildagliptin 100 mg SR once daily or Vildagliptin 50mg twice daily when used along with metformin 1000 mg?
The question has recently been addressed in a recent research published in the National Journal of Physiology, Pharmacy and Pharmacology.
In conversation with Prof (Dr.) Nilanjan Sengupta, co-author of the study, from the Department of Endocrinology, Nil Ratan Sircar Medical College and Hospital, Kolkata, West Bengal, India, who discusses about the effectiveness and safety of vildagliptin 50 mg twice daily with vildagliptin 100 mg SR tablet once daily in Type 2 DM patients uncontrolled with metformin monotherapy.
Dr. Sengupta also provides insights about Diabetes mellitus management in Indian population.
Reference: National Journal of Physiology Pharmacy and Pharmacology Online 2022. © 2022 Rudra Paul, et al., DOI: 10.5455/njppp.2022.12.062851202217862022
Speakers
Dr. Nandita Mohan
BDS, MDS( Pedodontics and Preventive Dentistry)